GlassScriptPhysician profile
Ruchi Jayesh Patel
NPI 1831550003
$22,996.04
in general payments reported to CMS, 2019-2025
41 companies · $6,157 in 2025
The $6,157 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,100 · 2022: $3,153 · 2023: $5,068 · 2024: $5,518 · 2025: $6,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,993.07 |
| Education | $749.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,505.19 | 2021-2025 | |
| Janssen Biotech, INC. | $2,941.75 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,721.82 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,511.19 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $1,375.36 | 2021-2025 | |
| Leo Pharma INC. | $1,301.07 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $1,258.04 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $978.86 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $952.81 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $722.59 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Pfizer INC. | $668.96 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $597.15 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $478.44 | 2022-2024 | Vtama |
| Ucb, INC. | $423.88 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $387.30 | 2021-2025 | Nemluvio, Aklief, Oracea |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339.20 | 2021-2025 | Otezla, Otezla |
| Almirall LLC | $295.33 | 2021-2025 | Klisyri, Seysara |
| Vyne Pharmaceuticals INC. | $232.69 | 2021 | |
| Epi Health, LLC | $231.57 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $224.12 | 2022-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $210.97 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.00 | 2022-2025 | Spevigo |
| Journey Medical Corporation | $174.50 | 2021-2023 | |
| Regeneron Pharmaceuticals, INC. | $153.97 | 2025 | Dupixent |
| Verrica Pharmaceuticals INC. | $149.53 | 2023-2024 | Ycanth |
| Mayne Pharma Commercial LLC | $148.66 | 2025 | |
| Biofrontera INC. | $131.95 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Abbott Laboratories | $126.51 | 2023 | Confirm Rx |
| Fresenius Kabi USA, LLC | $113.57 | 2023-2025 | |
| Organon LLC | $109.08 | 2023-2025 | Vtama, Hadlima |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Ani Pharmaceuticals, INC. | $79.73 | 2024 | Purified Cortrophin Gel |
| Botanix Sb INC | $35.49 | 2025 | Sofdra |
| Mallinckrodt Hospital Products INC. | $32.35 | 2025 | Acthar |
| Convatec INC. | $23.17 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.26 | 2021 | |
| Kyowa Kirin, INC. | $18.45 | 2023 | Poteligeo |
| Paratek Pharmaceuticals, INC. | $17.20 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $14.01 | 2024 | Simlandi |
| Genentech, INC. | $13.23 | 2023 | Erivedge |
| Mylan Institutional INC. | $13.10 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.